Document:

Exhibit
4.2

 

NEITHER
THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

COMMON
STOCK PURCHASE WARRANT

 

ONCBIOMUNE
PHARMACEUTICALS, inc.

 

	Warrant
    Shares: 656,674,588	 	Issue
    Date: June 5, 2020

 

THIS
COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, Doug Mergenthaler (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after
the Issue Date and on or after the filing of an amendment to the Company’s Articles of Incorporation to increase the number
of shares of the Company’s Common Stock that the Company is authorized to issue with the Secretary of State of the State
of Nevada (the “Initial Exercise Date”) and on or prior to the close of business on the Termination Date (as
defined below) but not thereafter, to subscribe for and purchase from OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the
“Company”), of up to 656,674,588 shares (subject to adjustment hereunder, the “Warrant Shares”)
of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”). This Warrant is being issued
in connection with the Asset Purchase Agreement, dated May 12, 2020 by and between the Company and Avant Diagnostics, Inc. (“Avant”)
pursuant to which the Company is acquiring substantially all of the assets of Avant. This Warrant is being issued in exchange
for and replaces the Common Stock Purchase Warrant, dated November 27, 2019, issued by Avant to the Holder to purchase 275,500
shares of common stock of Avant (the “Original Warrant”), after which the Original Warrant will be cancelled
and be of no further force and effect.

 

Section
1. Exercise; Termination Date.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto
as Annex A; and, within three (3) Business Days of the date said Notice of Exercise is delivered to the Company, the Company
shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s
check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Business Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. In the event
of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof. As used herein, “Business Day”
means any day except Saturday, Sunday or any other day on which commercial banks located in the State of Nevada are authorized
or required by law to be closed for business.

 

    	1

     

    

 

b)
Exercise Price. The exercise price (the “Exercise Price”) of this Warrant shall be $0.00214 per Warrant
Share, subject to adjustment hereunder.

 

c)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for the Warrant Shares purchased or exercised hereunder shall be transmitted
by the Company’s transfer agent to the Holder by crediting the account of the Holder’s broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if the Company is then a participant
in such system and there is an effective registration statement permitting the resale of the Warrant Shares and otherwise by physical
delivery to the address specified by the Holder in the Notice of Exercise within three (3) Business Days from the delivery to
the Company of the Notice of Exercise Form, surrender of this Warrant (if required), and payment of the aggregate Exercise Price
(unless cashless exercise is utilize) as set forth above (the “Warrant Share Delivery Date”). This Warrant
shall be deemed to have been exercised on the date the Exercise Price is received by the Company (or notice of cashless exercise
is received). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been
exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to
Section 1(c)(v) prior to the issuance of such shares, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for
by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Company’s transfer agent to transmit to the Holder a certificate
or the certificates representing the Warrant Shares pursuant to Section 1(c)(i) by the Warrant Share Delivery Date, then,
the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued
in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder, and such other documentation as the Company may require regarding the investor
status of the assignee, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto.

 

    	2

     

    

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

d)
Termination Date. This Warrant shall be exercisable from the Initial Exercise Date until November 27, 2024.

 

Section
2. Certain Adjustments.

 

a)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one
or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another person or group of persons whereby
such other person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder, the number, class, and series of shares of stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a
result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of
this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 2(a)
pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance
to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the
date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity
had been named as the Company herein.

 

    	3

     

    

 

b)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged, subject to the limitation on fractional shares
in Section 2(d)(iv). Any adjustment made pursuant to this Section 2(b) shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.

 

c)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be.

 

d)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and setting forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number of email address as it shall appear upon the Warrant Register
of the Company, at least five (5) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. The Holder is entitled to exercise this Warrant during the period commencing on the date
of such notice to the effective date of the event triggering such notice.

 

    	4

     

    

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the reasonable conditions and documentation
required by the Company, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with
a written assignment of this Warrant substantially in the form attached hereto as Annex B (the “Assignment Form”),
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the
Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall
be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
4. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(a).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve, from its
authorized and unissued Common Stock, a sufficient number of shares to provide for the issuance of the Warrant Shares upon the
exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary
certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of
any applicable law or regulation, or of any requirements of the business market upon which the Common Stock may be listed. The
Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant
will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously with such issue).

 

    	5

     

    

 

e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined by applying the laws of the State of Nevada, without regard to its conflicts of laws provisions.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant will have restrictions
upon resale imposed by state and federal securities laws unless (i) such Warrant Shares are registered; or (ii) the resale of
the Warrant Shares satisfies an exemption from registration under the Securities Act.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the
fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any
of its rights, powers or remedies hereunder.

 

h)
Notices. All notices and other communications from the Company to the Holder of this Warrant shall be sent by electronic
transmission or overnight courier or shall be mailed by first class registered or certified mail, postage prepaid, at such address
as may have been furnished to the Company in writing by such Holder. All such notices and communications shall, when mailed, be
effective when deposited in the mails and, when sent by electronic transmission or overnight courier, delivered, be effective
when received.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

j)
Successors and Assigns. Subject to applicable federal and state securities laws, this Warrant and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this
Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

k)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	6

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	ONCBIOMUNE
    PHARMACEUTICALS, INC.
	 	 
	 	By	/s/
                                         Andrew Kucharchuk

	 	Name:	Andrew
    Kucharchuk
	 	Title:	President
    and Chief Executive Officer

 

    	 

     

    

 

ANNEX
A

 

NOTICE
OF EXERCISE

 

To:
ONCBIOMUNE PHARMACEUTICALS, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and

 

(2)
Payment shall take the form of lawful money of the United States:

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name
as is specified below:

 

_______________________________

 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D,
promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ___________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _____________________________________________________

Name
of Authorized Signatory: _______________________________________________________________________

Title
of Authorized Signatory: ________________________________________________________________________

Date:
___________________________________________________________________________________________

 

    	 

     

    

 

ANNEX
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this
form and supply required information.

Do
not use this form to exercise the Warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

	 	 	Dated:
    ______________, ___________
	 	 	 
	 	Holder’s
    Signature:	_______________________________
	 	 	 
	 	Holder’s
    Address:	_______________________________

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Exhibit
10.1

 

EXCHANGE
AGREEMENT

 

THIS
EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals,
Inc., a Nevada corporation (the “Company”), and such persons listed on Schedule I who have executed
a signature page to this Agreement (each, an “Investor”).

 

WHEREAS,
the Investor has previously acquired various securities from the Company in the form of promissory notes and/or warrants issued
by the Company, as set forth on Schedule I (the “Securities”).

 

WHEREAS,
the Company has authorized a new series of Convertible Preferred Stock of the Company designated as Series C-1 Convertible Preferred
Stock, $0.0001 par value (the “Series C-1”), the terms of which are set forth in the Certificate of Designations
for such series of Series C-1 Preferred Stock (the “Certificate of Designations”) in the form attached hereto
as Exhibit A.

 

WHEREAS,
subject to the satisfaction of the conditions set forth herein, the Company and each Investor desire to enter into a transaction
wherein the Company shall issue such aggregate number of shares of Series C-1 in exchange for each of the Securities as set forth
on Schedule I.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree
as follows:

 

1.
Exchange. The closing of the Exchange (the “Closing”) will occur on or before May 31, 2020 (or such
later date as the parties hereto may agree) following the satisfaction or waiver of the conditions set forth herein (such date,
the “Closing Date”). On the Closing Date, subject to the terms and conditions of this Agreement, each Investor
shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the “Securities Act”),
exchange the Securities for (i) shares of the Series C-1 and (ii) Options (as defined below) to purchase shares of the Company’s
wholly-owned subsidiary, OncBioMune Sub, Inc., a Nevada corporation (“Sub”) (in the amounts and pursuant to
the terms set forth in Section 1.8 below). At the Closing, the following transactions shall occur (such transactions in this Section
1, the “Exchange”):

 

1.1.
Delivery of Securities. On the Closing Date, the Company shall issue the Series C-1 and Options to each Investor (or its
designees); provided that each Investor has complied with its obligations in this Section 1. Promptly after the Closing
Date, the Company shall deliver a certificate evidencing the Series C-1 to the Investor. On the Closing Date, the Investor shall
be deemed for all corporate purposes to have become the holder of record of the Series C-1 and shall have the right to convert
the Series C-1, irrespective of the date the Company delivers the certificate evidencing the Series C-1 to each Investor.

 

1.2.
No Rights Following Exchange. Upon receipt of the Series C-1 and Options in accordance with Section 1.1, each Investor’s
rights under the Securities shall be extinguished (including, without limitation, the rights to receive, as applicable, any principal,
premium, make-whole amount, accrued and unpaid interest, dividends or other payment thereon or any other shares of common stock,
$0.0001 par value (“Common Stock”) with respect thereto (whether upon in connection with a fundamental transaction,
event of default or otherwise)). In consideration for the issuance of the Series C-1 and the Options, each Investor hereby irrevocably
waives any obligations of the Company under the Securities or any purchase agreement, security agreement, pledge agreement, warrant,
guarantee or any other document executed in connection with the issuance of the Securities.

 

    	 	 	 

    	 	 	 

    

 

1.3.
Further Assurances. The Company and each Investor shall execute and/or deliver such other documents and agreements as are
customary and reasonably necessary to effectuate the Exchange.

 

1.4.
Termination Before Closing. If the Closing has not occurred on or prior to April 30, 2020, any Investor shall have the
right, by delivery of written notice to the Company to terminate this Agreement (such date, the “Termination Date”).
From the date hereof until the earlier of (x) the Closing Date and (y) the Termination Date, each Investor shall forbear from
taking any actions with respect to the Securities not explicitly set forth herein, including, without limitation, conversions,
exercises, redemptions, exchanges or delivery of written notice to the Company to require the conversion, exercise, redemption
or exchange of any of the Securities.

 

1.5.
Representations and Warranties True at Closing. It shall be a condition to the obligation of the Investor on the one hand
and Company on the other hand, to consummate the Exchange contemplated hereunder that the other party’s representations
and warranties contained herein are true and correct on the Closing Date with the same effect as though made on such date, unless
waived in writing by the party to whom such representations and warranties are made.

 

1.6.
Deliveries. At or before the Closing, each Investor shall deliver or cause to be delivered to K&L Gates, LLP, as counsel
to the Company, (i) the Securities held by such Investor free and clear of all liens, encumbrances, security interests, options
or other purchase rights, equities, charges, claims, pledges, defects of title or other restrictions of any kind (other than federal
and state securities laws) (ii) the executed Agreement and (iii) other items required to effectuate the Exchange.

 

1.7.
Senior Securities. The Closing and the obligation of the Investor to exchange its securities are subject to the cancellation
of the Company’s outstanding Series B Preferred Stock and the filing of a Certificate of Withdrawal eliminating the rights
and preferences thereunder. The capitalization of the Company immediately after the effectiveness of this Exchange and the exchanges
of the other outstanding securities will be as set forth on Exhibit B hereto.

 

1.8.
Options.

 

1.8.1.
The Company shall issue to each Investor an exclusive option to acquire shares of common stock of the Sub in the amounts set forth
on Schedule II hereto for a payment of $0.10 per share (the “Options”).

 

    	 	2	 

    	 	 	 

    

 

1.8.2.
Each Investor may deliver notice to the Company of its desire to exercise (“Exercise Notice”) its Options at
any time during the period from the Closing Date through April 30, 2021. Within ten (10) days of receipt by the Company of Exercise
Notices from Investors holding Options covering a majority of the shares of the Sub (the “Majority”), the Company
shall deliver a written notice to all Investors (the “Company Notice”) notifying them that the Company has
received such Exercise Notices from the Majority and the date of the closing of the purchase of the shares of Sub by such Majority
(the “Sub Closing”), which date will be not less than sixteen (16) days from the date of such notice. Such
Company Notice shall also include a notification to any Investor who wishes to exercise its Options but has not delivered an Exercise
Notice, that it must do so within fifteen (15) days following the date of the Company Notice in order to participate in the Sub
Closing. In the event the Company does not receive an Exercise Notice from any Investor, then such Investor’s Options shall
be automatically cancelled (the “Cancelled Options”) on the sixteenth (16th) day following the date of the
Company Notice and such Investors will have no rights and the Company no additional obligations under such Cancelled Options.

 

1.8.3.
The shares of the Sub underlying the Cancelled Options shall be divided pro rata among the Investors who timely deliver
Exercise Notices (“Participating Investors”). Each Participating Investor’s pro rata share shall
be equal to the product obtained by multiplying: (i) the aggregate number of shares underlying the Cancelled Options, by (ii)
a fraction, the numerator of which is the number of Options owned by such Investor on the date the Company Notice is delivered
and the denominator of which is the total number of Options granted on the Closing Date. On the date of the Sub Closing, each
Participating Investor shall deliver the exercise price for its Options to the Company in cash, and the Company shall issue to
each Investor the number of shares of the Sub underlying their Options plus any shares underlying Cancelled Options, if
any, to which they are entitled.

 

2.
Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor that:

 

2.1.
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Nevada. The Company is duly qualified to transact business and is in good standing in
each jurisdiction in which the failure to so qualify would have a Material Adverse Effect (as defined below) on its business or
properties. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on the business,
properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company
and its Subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange
(as defined below) or by the agreements and instruments to be entered into (or entered into) in connection herewith or therewith,
or on the authority or ability of the Company to perform its obligations under this Agreement or the Exchange.

 

2.2.
Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for
the authorization, execution and delivery of this Agreement and the other Exchange and the performance of all obligations of the
Company hereunder and thereunder, and the authorization of the Exchange, the issuance (and reservation for issuance) of the Series
C-1 have been taken on or prior to the date hereof. The Certificate of Designations has been validly filed with the Secretary
of State of Nevada and, as of the date hereof and the Closing Date, remains in full force and effect.

 

    	 	3	 

    	 	 	 

    

 

2.3.
Valid Issuance of the Series C-1. The Series C-1 shares when issued and delivered in accordance with the terms of this
Agreement, for the consideration expressed herein, and the Common Stock when issued in accordance with the terms of the Certificate
of Designations, for the consideration expressed therein, will be duly and validly issued, fully paid and non-assessable. Upon
conversion of the Series C-1, the Common Stock shall be freely tradable and may be sold under Rule 144 promulgated under the Securities
Act (“Rule 144”) subject to the requirements of Rule 144(i). If on the Closing Date, any Investor does not
already have such amount of shares reserved, the Company shall, within two business days after the Company files an amendment
of its Articles of Incorporation to increase the number of shares of Common Stock it is authorized to issue with the Secretary
of State of the State of Nevada, the Company shall reserve from its duly authorized capital stock not less than 125% of the maximum
number of shares of Common Stock issuable upon conversion of such Investor’s Series C-1 (assuming for purposes hereof that
such Series C-1 are convertible at the initial Conversion Price and any such reservation shall not take into account any limitations
on the conversion of the Series C-1 set forth herein).

 

2.4.
Compliance With Laws. The Company has not violated any law or any governmental regulation or requirement which violation
has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not received written notice of
any such violation.

 

2.5.
Consents; Waivers. No consent, waiver, approval or authority of any nature, or other formal action, by any individual,
a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government
or any department or agency thereof (each, a “Person”), not already obtained, is required in connection with
the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions provided for
herein and therein.

 

2.6.
Acknowledgment Regarding Investor’s Purchase of Series C-1. The Company acknowledges and agrees that each Investor
is acting solely for itself and not any other Investor in the capacity of arm’s length purchaser with respect to this Agreement
and the Exchange and the transactions contemplated hereby and thereby and that each Investor is not (i) an officer or director
of the Company, (ii) an “affiliate” of the Company (as defined in Rule 144 promulgated under the Securities Act),
or (iii) to the knowledge of the Company, a “beneficial owner” of more than 9.9% of the shares of Common Stock (as
defined for purposes of Rule 13d-3 under the Exchange Act). The Company further acknowledges that each Investor is not acting
as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Exchange and the transactions
contemplated hereby and thereby, and any advice given by the Investor or any of its representatives or agents in connection with
the Exchange and the transactions contemplated hereby and thereby is merely incidental to the Investor’s acceptance of the
Series C-1. The Company further represents to the Investor that the Company’s decision to enter into the Exchange has been
based solely on the independent evaluation by the Company and its representatives. The Company has not (i) received any consideration
from each Investor for the Series C-1 received in the Exchange, other than the Securities, (ii) paid any commission or remuneration
for the solicitation of the Exchange or (iii) offered any shares of the Series C-1 to any Person other than each Investor.

 

    	 	4	 

    	 	 	 

    

 

2.7.
Absence of Litigation. To the knowledge of the Company, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of
the Company, threatened against or affecting the Company, the Common Stock, the Securities or any of the Company’s officers
or directors in their capacities as such.

 

2.8.
Validity; Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf
of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in
accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the
enforcement of applicable creditors’ rights and remedies. The execution, delivery and performance by the Company of this
Agreement and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of the Company or (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company is a party or by which it is bound, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities or “Blue Sky” laws)
applicable to the Company, except in the case of clause (ii) above, for such conflicts, defaults or rights which would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

2.9.
Equal Treatment. None of the terms offered to any of the holders of the Company’s Securities listed on Schedule
I with respect to the Exchange, including, without limitation with respect to any consent, release, amendment, settlement,
or waiver relating to the Exchange (each an “Exchange Document”), is or will be more favorable to any other
holder of the Company’s Securities listed on Schedule I than those of each other Investor and this Agreement.

 

3.
Representations and Warranties of the Investor. Each Investor hereby represents, warrants and covenants that:

 

3.1.
Authorization. The Investor has full power and authority to enter into this Agreement, to perform its obligations hereunder
and to consummate the transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery
of this Agreement, the performance of its obligations hereunder and the consummation of the transactions contemplated hereby.

 

3.2.
Exchange Only. The Investor is a current holder of Securities and has not provided any consideration to the Company for
the Series C-1 received in the Exchange other than the Securities. Each Investor understands that: (i) the Securities have not
been and are not being registered under the Securities Act or any state securities laws, and the Series C-1 issued in the Exchange
may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) pursuant to Rule
144, or (C) pursuant to another exemption from registration under the Securities Act, including but not limited to Section 3(a)(9)
thereunder.

 

    	 	5	 

    	 	 	 

    

 

3.3.
No Governmental Review. The Investor understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Series C-1 or the fairness or suitability
of the investment in the Series C-1 nor have such authorities passed upon or endorsed the merits of the offering of the Series
C-1.

 

3.4.
Validity; Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf
of the Investor and shall constitute the legal, valid and binding obligations of the Investor enforceable against the Investor
in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally,
the enforcement of applicable creditors’ rights and remedies.

 

3.5.
Ownership of Securities. The Investor owns and holds, beneficially and of record, the entire right, title, and interest
in and to the Securities free and clear of all rights and liens (other than pledges or security interests (x) arising by operation
of applicable securities laws and (y) that the Investor may have created in favor of a prime broker under and in accordance with
its prime brokerage agreement with such broker). The Investor has full power and authority to transfer and dispose of the Securities
to the Company free and clear of any right or lien. Other than the transactions contemplated by this Agreement, there is no outstanding,
plan, pending proposal, or other right of any Person to acquire all or any part of the Securities or any shares of Common Stock
issuable upon conversion of the Securities.

 

3.6.
Release of Reserve. If prior to the date hereof, the Investor had a share reserve with West Coast Stock Transfer, the Company’s
transfer agent, it has instructed such transfer agent to release the amount shares of Common Stock the Investor has reserved in
excess of 125% of the maximum number of shares of Common Stock issuable upon conversion of the Series C-1 (assuming for purposes
hereof that such Series C-1 are convertible at the initial Conversion Price and any such reservation shall not take into account
any limitations on the conversion of the Series C-1 set forth herein).

 

4.
Additional Covenants.

 

4.1.
Disclosure. The Company shall, on or before 8:30 a.m., Eastern time, on the fourth business day after the date of this
Agreement, file with the Securities and Exchange Commission a Current Report on Form 8-K disclosing all material terms of the
transactions contemplated hereby and attaching the form of this Agreement and the Certificate of Designations as exhibits thereto
(collectively with all exhibits attached thereto, the “8-K Filing”). From and after the issuance of the 8-K
Filing, no Investor shall be in possession of any material, nonpublic information received from the Company or any of its subsidiaries
or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing. The
Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, provide any Investor with
any material, nonpublic information regarding the Company from and after the filing of the 8-K Filing without the express written
consent of such Investor. To the extent that the Company delivers any material, non-public information to an Investor without
such Investor’s express prior written consent, the Company hereby covenants and agrees that such Investor shall not have
any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees,
affiliates or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors,
employees, affiliates or agents or not to trade on the basis of, such material, non-public information. The Company shall not
disclose the name of any Investor in any filing, announcement, release or otherwise, unless such disclosure is required by law
or regulation. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all
confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries
or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Investor or any of its
affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that
each Investor will rely on the foregoing representations in effecting transactions in securities of the Company.

 

    	 	6	 

    	 	 	 

    

 

4.2.
Holding Period. For the purposes of Rule 144 of the Securities Act, the Company acknowledges that (i) the holding period
of the Securities may be tacked onto the holding period of the Series C-1 as long as no payment is made in connection with any
conversion, and (ii) the holding period of the Series C-1 may be tacked onto the holding period of the Common Stock, and the Company
agrees not to take a position contrary to this Section 4.2.

 

4.3.
Blue Sky. The Company shall make all filings and reports relating to the Exchange required under applicable securities
or “Blue Sky” laws of the states of the United States following the date hereof, if any.

 

4.4.
Fees and Expenses. Except as otherwise set forth above, each party to this Agreement shall pay the fees and expenses of
its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement.

 

4.5.
Equal Treatment. Each Investor hereby acknowledge and agree that, in accordance with the terms of existing agreements with
the Company relating to the Securities, the Company is obligated to present the terms of this Exchange to each holder of the Company’s
Securities on Schedule I; provided that each agreement shall be separately agreed with each holder of the Company’s
Securities and shall not in any way be construed as the Investor or any other holder of the Company’s Securities acting
in concert or as a group with respect to the purchase, disposition or voting of securities of the Company or otherwise. If, and
whenever on or after the date hereof, the Company enters into an Exchange Document other than in compliance with Section 2.9,
then (i) the Company shall provide notice thereof to each Investor immediately following the occurrence thereof and (ii) the terms
and conditions of this Agreement shall be, without any further action by each Investor or the Company, automatically amended and
modified such that the Investor shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set
forth in such Exchange Document, provided that upon written notice to the Company at any time any Investor may elect not to accept
the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement
shall apply to such Investor as it was in effect immediately prior to such amendment or modification as if such amendment or modification
never occurred with respect to such Investor. The provisions of this Section 4.5 shall apply similarly and equally to each
Exchange Document.

 

    	 	7	 

    	 	 	 

    

 

4.6.
Issuance of Unrestricted Common Stock. The Company agrees to take all actions, including, without limitation, the issuance
by its legal counsel, or any legal counsel reasonably acceptable to the Company, of any legal opinions, to issue unrestricted
Common Stock pursuant to Rule 144 in the connection of any sale of Common Stock issued upon conversion of Series C-1 by any Investor;
provided that each such investor provides customary representation letters and all other such documentation as required by counsel
to the Company to issue a legal opinion.

 

5.
Miscellaneous

 

5.1.
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or their respective successors
and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.

 

5.2.
Governing Law; Exclusive Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state or federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING
OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

5.3.
Notices. All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing,
and shall be sufficiently given if delivered to the addressees in person, by FedEx or similar overnight next business day delivery,
or by email followed by overnight next business day delivery, to the address as provided for on the signature page to this Agreement.

 

    	 	8	 

    	 	 	 

    

 

5.4.
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may
be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Investor.

 

5.5.
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded
and shall be enforceable in accordance with its terms so long as this Agreement as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in
good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect
of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

5.6.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

 

5.7.
Survival. Sections 4 and 5 of this Agreement shall survive the Closing and delivery of the Series C-1.

 

[SIGNATURES
ON THE FOLLOWING PAGE]

 

    	 	9	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	OncBioMune
    Pharmaceuticals, INC.
	 	 	 
	 	By:	/s/
                                         Andrew Kucharchuk               

	 	Name:
    	Andrew
    Kucharchuk
	 	Title:
    	Chief
    Executive Officer
	 	 
	 	Address
    for Notices:
	 	 
	 	11441
        Industriplex Blvd, Suite 190

        Baton
        Rouge, LA 70809

        Email:
        akucha1.obmp@gmail.com

 

    	 	 	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	INVESTORS:
	 	 
	 	_______________________________
	 	 
	 	By:
    _______________________________
	 	Name:
    _______________________________
	 	Title:
    ________________________________
	 	 
	 	Address
    for Notices:
	 	 
	 	                                                         
	 	 
	 	                                                        
	 	 
	 	                                                        
	 	 
	 	Email:
                                              
	 	 
	 	EIN#:
    ___________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]